title: [Clinical implication of cyclosporin for rheumatoid arthritis].
abstract: Cyclosporin is a non-cytotoxic immunomodulating drug which inhibits NF-AT-dependent IL-2 transcription in lymphocytes. Cyclosporin is, therefore, beneficial as a monotherapy or as a combined therapy with methotrexate for refractory rheumatoid arthritis (RA). We also document that cyclosporin recovers the low concentration of intracellular multidrugs in lymphocytes by competitively binding to P-glycoprotein, a product of multidrug resistance gene-1, in vitro. Thus, cyclosporin could be used for the reversal of multidrug resistance, experienced in patients with longterm treated RA.
authors.affiliation: First Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan.
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Shizuyo
authors.initials: S
authors.lastname: Tsujimura
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D016572:Cyclosporine / Q000008:administration & dosage* / Q000737:chemistry; D018432:Drug Resistance, Multiple; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate